| Year |
Citation |
Score |
| 2021 |
Fridjonsdottir E, Shariatgorji R, Nilsson A, Vallianatou T, Odell LR, Schembri LS, Svenningsson P, Fernagut PO, Crossman AR, Bezard E, Andrén PE. Mass spectrometry imaging identifies abnormally elevated brain l-DOPA levels and extrastriatal monoaminergic dysregulation in l-DOPA-induced dyskinesia. Science Advances. 7. PMID 33523980 DOI: 10.1126/sciadv.abe5948 |
0.655 |
|
| 2020 |
Bezard E, Li Q, Hulme H, Fridjonsdottir E, Nilsson A, Pioli E, Andren PE, Crossman AR. µ opioid receptor agonism for L-DOPA-induced dyskinesia in Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. PMID 32690616 DOI: 10.1523/JNEUROSCI.0610-20.2020 |
0.712 |
|
| 2018 |
Cenci MA, Crossman AR. Animal models of l-dopa-induced dyskinesia in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 29488257 DOI: 10.1002/mds.27337 |
0.452 |
|
| 2015 |
Bastide MF, Meissner WG, Picconi B, Fasano S, Fernagut PO, Feyder M, Francardo V, Alcacer C, Ding Y, Brambilla R, Fisone G, Jon Stoessl A, Bourdenx M, Engeln M, Navailles S, ... ... Crossman AR, et al. Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease. Progress in Neurobiology. PMID 26209473 DOI: 10.1016/J.Pneurobio.2015.07.002 |
0.801 |
|
| 2014 |
Shariatgorji M, Nilsson A, Goodwin RJ, Källback P, Schintu N, Zhang X, Crossman AR, Bezard E, Svenningsson P, Andren PE. Direct targeted quantitative molecular imaging of neurotransmitters in brain tissue sections. Neuron. 84: 697-707. PMID 25453841 DOI: 10.1016/J.Neuron.2014.10.011 |
0.631 |
|
| 2014 |
Ko WK, Martin-Negrier ML, Bezard E, Crossman AR, Ravenscroft P. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease. Neurobiology of Disease. 70: 138-48. PMID 24969021 DOI: 10.1016/j.nbd.2014.06.013 |
0.716 |
|
| 2014 |
Kobylecki C, Burn DJ, Kass-Iliyya L, Kellett MW, Crossman AR, Silverdale MA. Randomized clinical trial of topiramate for levodopa-induced dyskinesia in Parkinson's disease. Parkinsonism & Related Disorders. 20: 452-5. PMID 24521874 DOI: 10.1016/j.parkreldis.2014.01.016 |
0.391 |
|
| 2014 |
Bourdenx M, Nilsson A, Wadensten H, Fälth M, Li Q, Crossman AR, Andrén PE, Bezard E. Abnormal structure-specific peptide transmission and processing in a primate model of Parkinson's disease and l-DOPA-induced dyskinesia. Neurobiology of Disease. 62: 307-12. PMID 24148855 DOI: 10.1016/J.Nbd.2013.10.016 |
0.787 |
|
| 2013 |
Obeso JA, Guridi J, Nambu A, Crossman AR. Motor manifestations and basal ganglia output activity: the paradox continues. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 416-8. PMID 23494928 DOI: 10.1002/mds.25358 |
0.306 |
|
| 2013 |
Kobylecki C, Crossman AR, Ravenscroft P. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia. Experimental Neurology. 247: 476-84. PMID 23360800 DOI: 10.1016/j.expneurol.2013.01.019 |
0.487 |
|
| 2011 |
Kobylecki C, Hill MP, Crossman AR, Ravenscroft P. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 2354-63. PMID 21953539 DOI: 10.1002/mds.23867 |
0.507 |
|
| 2010 |
Kobylecki C, Cenci MA, Crossman AR, Ravenscroft P. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease. Journal of Neurochemistry. 114: 499-511. PMID 20456008 DOI: 10.1111/j.1471-4159.2010.06776.x |
0.495 |
|
| 2009 |
Hill M, Decamp E, Bezard E, Li Q, Schneider J, Crossman A. P2.010 Progressive MPTP non-human primate models that recapitulate non-motor symptoms of Parkinson's disease Parkinsonism & Related Disorders. 15: S90-S91. DOI: 10.1016/S1353-8020(09)70361-X |
0.656 |
|
| 2009 |
Schneider JS, Decamp E, Hill M, Bezard E, Crossman A, Murphy B, Mocaer E, Thomasson-Perret N. P4-342: Effects of the novel histamine H3 receptor antagonist S 38093 in a non-human primate model of cognitive dysfunction Alzheimer's & Dementia. 5: e31-e31. DOI: 10.1016/j.jalz.2009.07.140 |
0.6 |
|
| 2008 |
Scholz B, Svensson M, Alm H, Sköld K, Fälth M, Kultima K, Guigoni C, Doudnikoff E, Li Q, Crossman AR, Bezard E, Andrén PE. Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. Plos One. 3: e1589. PMID 18270577 DOI: 10.1371/Journal.Pone.0001589 |
0.689 |
|
| 2008 |
Millan MJ, Svenningsson P, Ashby CR, Hill M, Egeland M, Dekeyne A, Brocco M, Di Cara B, Lejeune F, Thomasson N, Munoz C, Mocaër E, Crossman A, Cistarelli L, Girardon S, et al. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. The Journal of Pharmacology and Experimental Therapeutics. 324: 600-11. PMID 18024787 DOI: 10.1124/jpet.107.132563 |
0.4 |
|
| 2007 |
Scheller D, Chan P, Li Q, Wu T, Zhang R, Guan L, Ravenscroft P, Guigoni C, Crossman AR, Hill M, Bezard E. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Experimental Neurology. 203: 415-22. PMID 17045989 DOI: 10.1016/J.Expneurol.2006.08.026 |
0.696 |
|
| 2007 |
Aubert I, Guigoni C, Li Q, Dovero S, Bioulac BH, Gross CE, Crossman AR, Bloch B, Bezard E. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biological Psychiatry. 61: 836-44. PMID 16950226 DOI: 10.1016/J.Biopsych.2006.06.038 |
0.798 |
|
| 2007 |
Kobylecki C, Ravenscroft P, Crossman A. 2.447 AMPA antagonists attenuate L-DOPA-induced abnormal involuntary movements in the 6-OHDA-lesioned rat model of Parkinson's disease Parkinsonism & Related Disorders. 13: S140. DOI: 10.1016/S1353-8020(08)70767-3 |
0.485 |
|
| 2006 |
Kultima K, Scholz B, Alm H, Sköld K, Svensson M, Crossman AR, Bezard E, Andrén PE, Lönnstedt I. Normalization and expression changes in predefined sets of proteins using 2D gel electrophoresis: a proteomic study of L-DOPA induced dyskinesia in an animal model of Parkinson's disease using DIGE. Bmc Bioinformatics. 7: 475. PMID 17067368 DOI: 10.1186/1471-2105-7-475 |
0.629 |
|
| 2006 |
Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 2090-5. PMID 16991143 DOI: 10.1002/mds.21106 |
0.725 |
|
| 2006 |
Nadjar A, Brotchie JM, Guigoni C, Li Q, Zhou SB, Wang GJ, Ravenscroft P, Georges F, Crossman AR, Bezard E. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 8653-61. PMID 16928853 DOI: 10.1523/Jneurosci.2582-06.2006 |
0.804 |
|
| 2005 |
van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, Brotchie JM. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 19: 1140-2. PMID 15894565 DOI: 10.1096/fj.04-3010fje |
0.762 |
|
| 2005 |
Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology. 48: 503-16. PMID 15755478 DOI: 10.1016/j.neuropharm.2004.11.008 |
0.801 |
|
| 2005 |
Guigoni C, Li Q, Aubert I, Dovero S, Bioulac BH, Bloch B, Crossman AR, Gross CE, Bezard E. Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 2102-7. PMID 15728850 DOI: 10.1523/Jneurosci.5059-04.2005 |
0.802 |
|
| 2005 |
Silverdale MA, Nicholson SL, Crossman AR, Brotchie JM. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 403-9. PMID 15593312 DOI: 10.1002/mds.20345 |
0.751 |
|
| 2004 |
Hill MP, Brotchie JM, Crossman AR, Bezard E, Michel A, Grimée R, Klitgaard H. Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets. Clinical Neuropharmacology. 27: 171-7. PMID 15319703 DOI: 10.1097/01.wnf.0000135478.70905.3d |
0.772 |
|
| 2004 |
Ismayilova N, Crossman A, Verkhratsky A, Brotchie J. Effects of adenosine A 1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats European Journal of Pharmacology. 497: 187-195. PMID 15306204 DOI: 10.1016/j.ejphar.2004.06.030 |
0.73 |
|
| 2004 |
Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology. 188: 471-9. PMID 15246846 DOI: 10.1016/J.Expneurol.2004.05.004 |
0.73 |
|
| 2004 |
Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ, Brotchie JM. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Experimental Neurology. 188: 128-38. PMID 15191809 DOI: 10.1016/j.expneurol.2004.03.022 |
0.73 |
|
| 2004 |
Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease Movement Disorders. 19: 554-560. PMID 15133820 DOI: 10.1002/mds.10693 |
0.722 |
|
| 2004 |
Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 310: 386-94. PMID 15004218 DOI: 10.1124/jpet.104.066191 |
0.806 |
|
| 2004 |
Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. The Journal of Pharmacology and Experimental Therapeutics. 309: 921-35. PMID 14978195 DOI: 10.1124/Jpet.103.062414 |
0.734 |
|
| 2004 |
Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. European Journal of Pharmacology. 485: 159-64. PMID 14757136 DOI: 10.1016/j.ejphar.2003.11.065 |
0.787 |
|
| 2004 |
Ravenscroft P, Chalon S, Brotchie JM, Crossman AR. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Experimental Neurology. 185: 36-46. PMID 14697317 DOI: 10.1016/j.expneurol.2003.09.001 |
0.766 |
|
| 2003 |
Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 1301-5. PMID 14639671 DOI: 10.1002/mds.10542 |
0.809 |
|
| 2003 |
Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Experimental Neurology. 183: 458-68. PMID 14552886 DOI: 10.1016/S0014-4886(03)00064-5 |
0.737 |
|
| 2003 |
Bezard E, Baufreton J, Owens G, Crossman AR, Dudek H, Taupignon A, Brotchie JM. Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 17: 2337-8. PMID 14525941 DOI: 10.1096/fj.03-0291fje |
0.792 |
|
| 2003 |
Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 872-83. PMID 12889076 DOI: 10.1002/mds.10464 |
0.707 |
|
| 2003 |
Segovia G, Mora F, Crossman AR, Brotchie JM. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 138-49. PMID 12539206 DOI: 10.1002/mds.10312 |
0.735 |
|
| 2003 |
Silverdale MA, Fox SH, Crossman AR, Brotchie JM. Potential nondopaminergic drugs for Parkinson's disease. Advances in Neurology. 91: 273-91. PMID 12442686 |
0.656 |
|
| 2002 |
Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of Cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease Movement Disorders. 17: 1180-1187. PMID 12465055 DOI: 10.1002/mds.10289 |
0.767 |
|
| 2002 |
Silverdale MA, Crossman AR, Brotchie JM. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. Experimental Neurology. 174: 21-8. PMID 11869030 DOI: 10.1006/exnr.2001.7854 |
0.75 |
|
| 2002 |
Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 145-9. PMID 11835452 DOI: 10.1002/mds.1280 |
0.696 |
|
| 2001 |
Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 57: 2108-11. PMID 11739835 DOI: 10.1212/Wnl.57.11.2108 |
0.714 |
|
| 2001 |
Hille CJ, Fox SH, Maneuf YP, Crossman AR, Brotchie JM. Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. Experimental Neurology. 172: 189-98. PMID 11681851 DOI: 10.1006/exnr.2001.7763 |
0.754 |
|
| 2001 |
Henry B, Fox SH, Crossman AR, Brotchie JM. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Experimental Neurology. 171: 139-46. PMID 11520128 DOI: 10.1006/exnr.2001.7727 |
0.741 |
|
| 2001 |
Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 6853-61. PMID 11517273 DOI: 10.1523/Jneurosci.21-17-06853.2001 |
0.819 |
|
| 2001 |
Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 642-50. PMID 11481687 DOI: 10.1002/mds.1148 |
0.753 |
|
| 2001 |
Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Experimental Neurology. 169: 400-6. PMID 11358453 DOI: 10.1006/exnr.2001.7649 |
0.734 |
|
| 2001 |
Bezard E, Ravenscroft P, Gross CE, Crossman AR, Brotchie JM. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys. Neurobiology of Disease. 8: 343-50. PMID 11300729 DOI: 10.1006/nbdi.2000.0375 |
0.826 |
|
| 2001 |
Bezard E, Crossman AR, Gross CE, Brotchie JM. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 15: 1092-4. PMID 11292678 DOI: 10.1096/Fj.00-0637Fje |
0.816 |
|
| 2001 |
Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease The Journal of Neuroscience. 21: 6853-6861. DOI: 10.1523/JNEUROSCI.21-17-06853.2001 |
0.8 |
|
| 2000 |
Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology. 165: 136-42. PMID 10964492 DOI: 10.1006/Exnr.2000.7444 |
0.76 |
|
| 2000 |
Arbuthnott G, Crossman A, Payne T. Symposium on neurobiology of the basal ganglia Journal of Anatomy. 196: 499-499. PMID 10960285 DOI: 10.1046/J.1469-7580.2000.19640499.X |
0.425 |
|
| 2000 |
Crossman AR. Functional anatomy of movement disorders. Journal of Anatomy. 196: 519-25. PMID 10923984 DOI: 10.1017/S0021878299005981 |
0.427 |
|
| 2000 |
Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 14: 1432-8. PMID 10877836 DOI: 10.1096/Fasebj.14.10.1432 |
0.746 |
|
| 1999 |
Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 744-53. PMID 10495035 DOI: 10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7 |
0.76 |
|
| 1999 |
Henry B, Crossman AR, Brotchie JM. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Experimental Neurology. 155: 204-20. PMID 10072296 DOI: 10.1006/exnr.1998.6996 |
0.764 |
|
| 1998 |
Henry B, Crossman AR, Brotchie JM. Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia. Advances in Neurology. 78: 53-61. PMID 9750903 |
0.653 |
|
| 1998 |
Brotchie JM, Henry B, Hille CJ, Crossman AR. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. Advances in Neurology. 78: 41-52. PMID 9750902 |
0.69 |
|
| 1998 |
Crossman AR, Brotchie JM. Pathophysiology of dystonia. Advances in Neurology. 78: 19-25. PMID 9750899 |
0.62 |
|
| 1998 |
Richter A, Brotchie JM, Crossman AR, Löscher W. [3H]-2-deoxyglucose uptake study in mutant dystonic hamsters: abnormalities in discrete brain regions of the motor system. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 718-25. PMID 9686781 DOI: 10.1002/mds.870130419 |
0.7 |
|
| 1998 |
Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Experimental Neurology. 151: 334-42. PMID 9628768 DOI: 10.1006/exnr.1998.6819 |
0.747 |
|
| 1998 |
Hughes NR, McKnight AT, Woodruff GN, Hill MP, Crossman AR, Brotchie JM. Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 228-33. PMID 9539334 DOI: 10.1002/mds.870130206 |
0.723 |
|
| 1998 |
Duty S, Henry B, Crossman AR, Brotchie JM. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Experimental Neurology. 150: 223-34. PMID 9527891 DOI: 10.1006/exnr.1997.6771 |
0.728 |
|
| 1997 |
Maneuf YP, Crossman AR, Brotchie JM. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Experimental Neurology. 148: 265-70. PMID 9398468 DOI: 10.1006/exnr.1997.6645 |
0.726 |
|
| 1996 |
Maneuf YP, Crossman AR, Brotchie JM. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse (New York, N.Y.). 22: 382-5. PMID 8867032 DOI: 10.1002/(SICI)1098-2396(199604)22:4<382::AID-SYN9>3.0.CO;2-7 |
0.646 |
|
| 1996 |
Maneuf YP, Nash JE, Crossman AR, Brotchie JM. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. European Journal of Pharmacology. 308: 161-4. PMID 8840127 DOI: 10.1016/0014-2999(96)00326-3 |
0.659 |
|
| 1996 |
Maneuf YP, Duty S, Hille CJ, Crossman AR, Brotchie JM. Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease. Experimental Neurology. 139: 12-6. PMID 8635558 DOI: 10.1006/exnr.1996.0075 |
0.687 |
|
| 1995 |
Maneuf YP, Mitchell IJ, Crossman AR, Woodruff GN, Brotchie JM. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Research. 683: 102-8. PMID 7552334 DOI: 10.1016/0006-8993(95)00358-W |
0.755 |
|
| 1994 |
Maneuf YP, Mitchell IJ, Crossman AR, Brotchie JM. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Experimental Neurology. 125: 65-71. PMID 8307125 DOI: 10.1006/exnr.1994.1007 |
0.718 |
|
| 1994 |
Féger J, Bevan M, Crossman AR. The projections from the parafascicular thalamic nucleus to the subthalamic nucleus and the striatum arise from separate neuronal populations: a comparison with the corticostriatal and corticosubthalamic efferents in a retrograde fluorescent double-labelling study. Neuroscience. 60: 125-32. PMID 8052406 DOI: 10.1016/0306-4522(94)90208-9 |
0.648 |
|
| 1994 |
Griffiths PD, Perry RH, Crossman AR. A detailed anatomical analysis of neurotransmitter receptors in the putamen and caudate in Parkinson's disease and Alzheimer's disease. Neuroscience Letters. 169: 68-72. PMID 8047295 DOI: 10.1016/0304-3940(94)90358-1 |
0.464 |
|
| 1994 |
Bevan MD, Bolam JP, Crossman AR. Convergent synaptic input from the neostriatum and the subthalamus onto identified nigrothalamic neurons in the rat. The European Journal of Neuroscience. 6: 320-34. PMID 8019671 DOI: 10.1111/J.1460-9568.1994.Tb00275.X |
0.646 |
|
| 1994 |
Bevan MD, Crossman AR, Bolam JP. Neurons projecting from the entopeduncular nucleus to the thalamus receive convergent synaptic inputs from the subthalamic nucleus and the neostriatum in the rat. Brain Research. 659: 99-109. PMID 7529649 DOI: 10.1016/0006-8993(94)90868-0 |
0.639 |
|
| 1993 |
Griffiths PD, Crossman AR. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease. Dementia (Basel, Switzerland). 4: 61-5. PMID 8358514 DOI: 10.1159/000107298 |
0.332 |
|
| 1993 |
Graham WC, Sambrook MA, Crossman AR. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Research. 602: 290-303. PMID 8095431 DOI: 10.1016/0006-8993(93)90694-I |
0.371 |
|
| 1993 |
Brotchie J, Crossman A, Mitchell I, Duty S, Carroll C, Cooper A, Henry B, Hughes N, Maneuf Y. Chemical signalling in the globus pallidus in parkinsonism Progress in Brain Research. 99: 125-139. PMID 7906423 DOI: 10.1016/S0079-6123(08)61342-4 |
0.694 |
|
| 1993 |
Page RD, Sambrook MA, Crossman AR. Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated parkinsonian monkey. Neuroscience. 55: 147-65. PMID 7688878 DOI: 10.1016/0306-4522(93)90462-O |
0.397 |
|
| 1992 |
Mitchell IJ, Boyce S, Sambrook MA, Crossman AR. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain : a Journal of Neurology. 115: 809-24. PMID 1628204 DOI: 10.1093/Brain/115.3.809 |
0.463 |
|
| 1992 |
Mitchell IJ, Crossman AR, Liminga U, Andren P, Gunne LM. Regional changes in 2-deoxyglucose uptake associated with neuroleptic-induced tardive dyskinesia in the Cebus monkey. Movement Disorders : Official Journal of the Movement Disorder Society. 7: 32-7. PMID 1557064 DOI: 10.1002/Mds.870070106 |
0.375 |
|
| 1992 |
Black MD, Crossman AR. Changes in dopamine D1 and D2 receptor binding in the substantia nigra following intrastriatal injection of a retrograde neurotoxin (volkensin). Neuroscience Letters. 134: 180-2. PMID 1534159 DOI: 10.1016/0304-3940(92)90511-5 |
0.396 |
|
| 1992 |
Black MD, Carey F, Crossman AR, Relton JK, Rothwell NJ. Lipocortin-1 inhibits NMDA receptor-mediated neuronal damage in the striatum of the rat. Brain Research. 585: 135-40. PMID 1387336 DOI: 10.1016/0006-8993(92)91198-N |
0.38 |
|
| 1992 |
Aziz TZ, Peggs D, Agarwal E, Sambrook MA, Crossman AR. Subthalamic nucleotomy alleviates parkinsonism in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-exposed primate. British Journal of Neurosurgery. 6: 575-82. PMID 1361741 DOI: 10.3109/02688699209002375 |
0.56 |
|
| 1992 |
Griffiths PD, Crossman AR. Receptor changes in the neocortex of post-mortem tissue in Parkinson's disease and Alzheimer's disease Dementia. 3: 239-246. DOI: 10.1159/000107023 |
0.402 |
|
| 1992 |
MORELLI M, FENU S, PINNA A, PONTIERI F, DI CG, MITCHELL IJ, BROTCHIE JM, CROSSMAN AR. INTERACTION BETWEEN NMDA RECEPTOR ANTAGONISTS AND DOPAMINERGIC AGONISTS IN THE 6-HYDROXYDOPAMINE MODEL OF PARKINSON Behavioural Pharmacology. 3: 24. DOI: 10.1097/00008877-199204001-00069 |
0.69 |
|
| 1991 |
Mitchell IJ, Brotchie JM, Brown GD, Crossman AR. Modeling the functional organization of the basal ganglia. A parallel distributed processing approach. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 189-204. PMID 1922123 DOI: 10.1002/mds.870060302 |
0.645 |
|
| 1991 |
Graham WC, Hill DR, Woodruff GN, Sambrook MA, Crossman AR. Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey. Neuroscience Letters. 131: 129-34. PMID 1791971 DOI: 10.1016/0304-3940(91)90353-U |
0.419 |
|
| 1991 |
Robertson RG, Graham WC, Sambrook MA, Crossman AR. Further investigations into the pathophysiology of MPTP-induced parkinsonism in the primate: an intracerebral microdialysis study of gamma-aminobutyric acid in the lateral segment of the globus pallidus. Brain Research. 563: 278-80. PMID 1786541 DOI: 10.1016/0006-8993(91)91545-C |
0.374 |
|
| 1991 |
Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 288-92. PMID 1758446 DOI: 10.1002/Mds.870060404 |
0.577 |
|
| 1991 |
Brotchie JM, Crossman AR. D-[3H]aspartate and [14C]GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents. Experimental Neurology. 113: 171-81. PMID 1651255 DOI: 10.1016/0014-4886(91)90173-A |
0.672 |
|
| 1991 |
Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 133-8. PMID 1647492 DOI: 10.1002/mds.870060208 |
0.718 |
|
| 1990 |
Mitchell IJ, Luquin R, Boyce S, Clarke CE, Robertson RG, Sambrook MA, Crossman AR. Neural mechanisms of dystonia: evidence from a 2-deoxyglucose uptake study in a primate model of dopamine agonist-induced dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 5: 49-54. PMID 2296259 DOI: 10.1002/mds.870050113 |
0.449 |
|
| 1990 |
Boyce S, Clarke CE, Luquin R, Peggs D, Robertson RG, Mitchell IJ, Sambrook MA, Crossman AR. Induction of chorea and dystonia in parkinsonian primates. Movement Disorders : Official Journal of the Movement Disorder Society. 5: 3-7. PMID 2296255 DOI: 10.1002/mds.870050103 |
0.331 |
|
| 1990 |
Robertson RG, Clarke CA, Boyce S, Sambrook MA, Crossman AR. The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography. Brain Research. 531: 95-104. PMID 2289139 DOI: 10.1016/0006-8993(90)90762-Z |
0.469 |
|
| 1990 |
Graham WC, Robertson RG, Sambrook MA, Crossman AR. Injection of excitatory amino acid antagonists into the medial pallidal segment of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treated primate reverses motor symptoms of parkinsonism. Life Sciences. 47: PL91-7. PMID 2250573 DOI: 10.1016/0024-3205(90)90376-3 |
0.371 |
|
| 1990 |
Graham WC, Clarke CE, Boyce S, Sambrook MA, Crossman AR, Woodruff GN. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Research. 514: 103-10. PMID 2192772 DOI: 10.1016/0006-8993(90)90440-M |
0.432 |
|
| 1990 |
Graham WC, Crossman AR, Woodruff GN. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Research. 514: 93-102. PMID 2113410 DOI: 10.1016/0006-8993(90)90439-I |
0.412 |
|
| 1990 |
Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Movement Disorders : Official Journal of the Movement Disorder Society. 5: 100-8. PMID 1970120 DOI: 10.1002/mds.870050203 |
0.386 |
|
| 1990 |
Griffiths PD, Sambrook MA, Perry R, Crossman AR. Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease. Journal of the Neurological Sciences. 100: 131-6. PMID 1965202 DOI: 10.1016/0022-510X(90)90023-G |
0.449 |
|
| 1990 |
Brotchie JM, Bevan MD, Mitchell IJ, Crossman AR. Anti-parkinsonian effects of EAA antagonists in the entopeduncular nucleus are due to an action at NMDA-like receptors European Journal of Pharmacology. 183: 943-944. DOI: 10.1016/0014-2999(90)92783-F |
0.781 |
|
| 1990 |
Bevan MD, Brotchie JM, Crossman AR. Intracerebral injections of the EAA antagonist kynurenate in the entopeduncular nucleus of the rat elicits a range of hyperkinetic disorders European Journal of Pharmacology. 183: 943. DOI: 10.1016/0014-2999(90)92782-E |
0.764 |
|
| 1989 |
Augood SJ, Emson PC, Mitchell IJ, Boyce S, Clarke CE, Crossman AR. Cellular localisation of enkephalin gene expression in MPTP-treated cynomolgus monkeys. Brain Research. Molecular Brain Research. 6: 85-92. PMID 2788792 DOI: 10.1016/0169-328X(89)90032-6 |
0.404 |
|
| 1989 |
Clarke CE, Boyce S, Robertson RG, Sambrook MA, Crossman AR. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Journal of the Neurological Sciences. 90: 307-14. PMID 2786926 DOI: 10.1016/0022-510X(89)90117-2 |
0.441 |
|
| 1989 |
Crossman AR, Peggs D, Boyce S, Luquin MR, Sambrook MA. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey. Neuropharmacology. 28: 1271-3. PMID 2687716 DOI: 10.1016/0028-3908(89)90221-9 |
0.518 |
|
| 1989 |
Mitchell IJ, Jackson A, Sambrook MA, Crossman AR. The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. Brain : a Journal of Neurology. 112: 1533-48. PMID 2597995 DOI: 10.1093/Brain/112.6.1533 |
0.352 |
|
| 1989 |
Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA, Crossman AR. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience. 32: 213-26. PMID 2586750 DOI: 10.1016/0306-4522(89)90120-6 |
0.414 |
|
| 1989 |
Crossman AR. Neural mechanisms in disorders of movement. Comparative Biochemistry and Physiology. a, Comparative Physiology. 93: 141-9. PMID 2568216 DOI: 10.1016/0300-9629(89)90201-6 |
0.365 |
|
| 1989 |
Robertson RG, Farmery SM, Sambrook MA, Crossman AR. Dyskinesia in the primate following injection of an excitatory amino acid antagonist into the medial segment of the globus pallidus. Brain Research. 476: 317-22. PMID 2539224 DOI: 10.1016/0006-8993(89)91252-3 |
0.334 |
|
| 1988 |
Leenders KL, Aquilonius SM, Bergström K, Bjurling P, Crossman AR, Eckernas SA, Gee AG, Hartvig P, Lundqvist H, Långström B. Unilateral MPTP lesion in a rhesus monkey: effects on the striatal dopaminergic system measured in vivo with PET using various novel tracers. Brain Research. 445: 61-7. PMID 3259152 DOI: 10.1016/0006-8993(88)91074-8 |
0.396 |
|
| 1988 |
Crossman AR, Mitchell IJ, Sambrook MA, Jackson A. Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea. Brain : a Journal of Neurology. 111: 1211-33. PMID 3179691 DOI: 10.1093/Brain/111.5.1211 |
0.406 |
|
| 1988 |
Clarke CE, Boyce S, Sambrook MA, Stahl SM, Crossman AR. Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Naunyn-Schmiedeberg's Archives of Pharmacology. 338: 35-8. PMID 2907097 DOI: 10.1007/BF00168809 |
0.424 |
|
| 1987 |
Clarke CE, Sambrook MA, Mitchell IJ, Crossman AR. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Journal of the Neurological Sciences. 78: 273-80. PMID 3495642 DOI: 10.1016/0022-510X(87)90041-4 |
0.384 |
|
| 1987 |
Crossman AR, Clarke CE, Boyce S, Robertson RG, Sambrook MA. MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 14: 428-35. PMID 3119180 DOI: 10.1017/S0317167100037859 |
0.504 |
|
| 1987 |
Graham WC, Crossman AR. Autoradiographic localization of dopamine D1 binding sites in areas receiving striatal input. European Journal of Pharmacology. 142: 479-81. PMID 2892688 DOI: 10.1016/0014-2999(87)90093-8 |
0.331 |
|
| 1986 |
Stuart AM, Mitchell IJ, Slater P, Unwin HL, Crossman AR. A semi-quantitative atlas of 5-hydroxytryptamine-1 receptors in the primate brain. Neuroscience. 18: 619-39. PMID 3748377 DOI: 10.1016/0306-4522(86)90058-8 |
0.326 |
|
| 1986 |
Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR. Neural mechanisms mediating 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced parkinsonism in the monkey: relative contributions of the striatopallidal and striatonigral pathways as suggested by 2-deoxyglucose uptake. Neuroscience Letters. 63: 61-5. PMID 3485267 DOI: 10.1016/0304-3940(86)90013-3 |
0.404 |
|
| 1986 |
Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism. Journal of Neural Transmission. Supplementum. 20: 41-6. PMID 3462325 |
0.311 |
|
| 1985 |
Patel S, Slater P, Crossman AR. A lesioning and 2-deoxyglucose study of the hyperactivity produced by an intra-accumbens dopamine agonist. Naunyn-Schmiedeberg's Archives of Pharmacology. 331: 334-40. PMID 4094623 DOI: 10.1007/BF00500815 |
0.393 |
|
| 1985 |
Mitchell IJ, Jackson A, Sambrook MA, Crossman AR. Common neural mechanisms in experimental chorea and hemiballismus in the monkey. Evidence from 2-deoxyglucose autoradiography. Brain Research. 339: 346-50. PMID 4027631 DOI: 10.1016/0006-8993(85)90102-7 |
0.362 |
|
| 1985 |
Mitchell IJ, Sambrook MA, Crossman AR. Subcortical changes in the regional uptake of [3H]-2-deoxyglucose in the brain of the monkey during experimental choreiform dyskinesia elicited by injection of a gamma-aminobutyric acid antagonist into the subthalamic nucleus. Brain : a Journal of Neurology. 108: 405-22. PMID 4005529 DOI: 10.1093/Brain/108.2.405 |
0.357 |
|
| 1985 |
Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neuroscience Letters. 61: 195-200. PMID 3878482 DOI: 10.1016/0304-3940(85)90424-0 |
0.434 |
|
| 1985 |
Crossman AR, Mitchell IJ, Sambrook MA. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology. 24: 587-91. PMID 3875056 DOI: 10.1016/0028-3908(85)90070-X |
0.383 |
|
| 1984 |
Féger J, Crossman AR. Identification of different subpopulations of neostriatal neurones projecting to globus pallidus or substantia nigra in the monkey: a retrograde fluorescence double-labelling study. Neuroscience Letters. 49: 7-12. PMID 6493600 DOI: 10.1016/0304-3940(84)90127-7 |
0.311 |
|
| 1981 |
Lee LA, Slater P, Crossman AR. The role of the substantia nigra in a striatally-evoked motor response in the rat: effects of intranigral drugs and lesions. Neuroscience. 6: 359-66. PMID 6164012 DOI: 10.1016/0306-4522(81)90129-9 |
0.397 |
|
| 1980 |
Lee LA, Crossman AR, Slater P. The neurological basis of striatally induced head-turning in the rat: the effects of lesions in putative output pathways. Neuroscience. 5: 73-9. PMID 7366844 DOI: 10.1016/0306-4522(80)90072-X |
0.374 |
|
| 1980 |
Slater P, Crossman AR. Effects of chronic morphine treatment on dopamine-mediated turning behaviour in rats and mice with 6-hydroxydopamine-induced unilateral nigro-striatal lesions. Neuropharmacology. 19: 289-95. PMID 7191487 DOI: 10.1016/0028-3908(80)90152-5 |
0.389 |
|
| 1980 |
Slater P, Blundell C, Crossman AR. The effects of narcotic analgesics on the turning behaviour of rats with 6-hydroxydopamine-induced unilateral nigro-striatal lesions. Neuropharmacology. 19: 187-93. PMID 6102357 DOI: 10.1016/0028-3908(80)90137-9 |
0.414 |
|
| 1979 |
Sambrook MA, Crossman AR, Slater P. Experimental torticollis in the marmoset produced by injection of 6-hydroxydopamine into the ascending nigrostriatal pathway. Experimental Neurology. 63: 583-93. PMID 107039 DOI: 10.1016/0014-4886(79)90173-0 |
0.404 |
|
| 1978 |
Crossman AR, Sambrook MA. The neurological basis of motor asymmetry following unilateral nigrostriatal lesions in the rat: the effect of secondary superior colliculus lesions. Brain Research. 159: 211-3. PMID 569529 DOI: 10.1016/0006-8993(78)90121-X |
0.334 |
|
| 1978 |
Crossman AR, Sambrook MA. Experimental torticollis in the monkey produced by unilateral 6-hydroxy-dopamine brain lesions. Brain Research. 149: 498-502. PMID 96912 DOI: 10.1016/0006-8993(78)90492-4 |
0.372 |
|
| 1977 |
Williams DJ, Crossman AR, Slater P. The efferent projections of the nucleus accumbens in the rat. Brain Research. 130: 217-27. PMID 884524 DOI: 10.1016/0006-8993(77)90271-2 |
0.33 |
|
| 1977 |
Crossman AR, Sambrook MA, Gergies SW, Slater P. The neurological basis of motor asymmetry following unilateral 6-hydroxydopamine brain lesions in the rat: the effect of motor decortication. Journal of the Neurological Sciences. 34: 407-14. PMID 591996 DOI: 10.1016/0022-510X(77)90156-3 |
0.384 |
|
| 1972 |
Crossman AR, Kerkut GA, Walker RJ. Electrophysiological studies on the axon pathways of specified nerve cells in the central ganglia of two insect species, Periplaneta americana and Schistocerca gregaria Comparative Biochemistry and Physiology -- Part a: Physiology. 43: 393-415. DOI: 10.1016/0300-9629(72)90199-5 |
0.404 |
|
| 1971 |
Crossman AR, Kerkut GA, Walker RJ. Axon pathways of electrically excitable nerve cell bodies in the insect central nervous system. The Journal of Physiology. 218: 55P-56P. PMID 5130634 |
0.403 |
|
| 1971 |
Walker RJ, Crossman AR, Woodruff GN, Kerkut GA. The effect of bicuculline on the gamma-aminobutyric acid (GABA) receptors of neurons of Periplaneta americana and Helix aspersa. Brain Research. 33: 75-82. PMID 4330215 DOI: 10.1016/0006-8993(71)90306-4 |
0.474 |
|
| 1971 |
Crossman AR, Kerkut GA, Pitman RM, Walker RJ. Electrically excitable nerve cell bodies in the central ganglia of two insect species Periplaneta americana and Schistocerca gregaria. Investigation of cell geometry and morphology by intracellular dye injection Comparative Biochemistry and Physiology -- Part a: Physiology. 40: 579-582,IN1-IN2,583-. DOI: 10.1016/0300-9629(71)90242-8 |
0.426 |
|
| Show low-probability matches. |